Savara, Inc. (SVRA)
5.355
-0.04
(-0.65%)
USD |
NASDAQ |
Sep 01, 16:00
5.355
0.00 (0.00%)
After-Hours: 20:00
Savara Research and Development Expense (Annual) : 81.40M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 81.40M |
| December 31, 2024 | 78.03M |
| December 31, 2023 | 44.26M |
| December 31, 2022 | 27.88M |
| December 31, 2021 | 28.99M |
| December 31, 2020 | 35.04M |
| December 31, 2019 | 38.78M |
| December 31, 2018 | 37.17M |
| December 31, 2017 | 18.51M |
| December 31, 2016 | 8.182M |
| December 31, 2015 | 28.26M |
| December 31, 2014 | 19.44M |
| December 31, 2013 | 12.90M |
| Date | Value |
|---|---|
| December 31, 2012 | 8.088M |
| December 31, 2011 | 5.758M |
| December 31, 2010 | 3.689M |
| December 31, 2009 | 6.284M |
| December 31, 2008 | 17.92M |
| December 31, 2007 | 15.93M |
| December 31, 2006 | 12.00M |
| December 31, 2005 | 8.682M |
| December 31, 2004 | 2.744M |
| December 31, 2003 | 0.749M |
| December 31, 2002 | 0.283M |
| December 31, 2001 | 0.9464M |
| December 31, 2000 | 1.017M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Gilead Sciences, Inc. | 5.688B |
| Insmed, Inc. | 771.09M |
| United Therapeutics Corp. | 550.00M |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| SELLAS Life Sciences Group, Inc. | 16.02M |